Study of Genomic, Environmental, Microbiome, and Metabolomic Factors in Infants at Risk for Celiac Disease
Led by Massachusetts General Hospital · Updated on 2026-04-17
500
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying celiac disease CD, a complex condition triggered by eating gluten found in wheat, rye, and barley. This study aims to understand how genes, environmental factors, the gut microbiome, and metabolomic profiles contribute to the development of CD, especially in children at higher risk due to family history. By examining these factors, the researchers hope to find ways to better predict and prevent CD in high-risk infants.
The study involves infants under 6 months old who have a first-degree relative with biopsy-confirmed celiac disease. Researchers will collect detailed information on genetics, birth method, antibiotic use, feeding method, illnesses, infections, and growth. They will regularly update this information every six months until the child reaches five years old. The study also focuses on analyzing gut bacteria and metabolites through stool samples and other biological assessments to see how these relate to disease development.
Participants will be followed from infancy up to five years of age with evaluations every six months. These include microbiome sequencing from stool samples, blood tests for gut permeability and immune responses, and questionnaires about health and diet. The main outcome is to track changes in gut bacteria composition over time, particularly around gluten introduction and the potential onset of autoimmunity. Secondary outcomes include monitoring gut permeability and immune markers to understand loss of gluten tolerance. The study will help identify early signs or risk factors for CD in at-risk infants.
CONDITIONS
Brief Title
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
Research Team
V
Victoria Kenyon, MHA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Newborns and infants less than 6 months of age who have not been introduced to solid foods (exclusive breast milk or formula diet)
First-degree relatives of patients affected with biopsy-proven CD
You will not qualify if you...
Infants older than 6 months of age
Inability or unwillingness of legal guardian/representative to give written informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 5 years
Participants who have a first-degree relative with celiac disease are observed over time. Information about their environment, medical history, and growth is collected to understand factors that may affect the development of celiac disease.
Visits every six months until age 5
Sample Collection
Duration - Up to 5 years
Biological samples are collected to study the gut microbiome and metabolomic profiles of participants and how these change over time in relation to celiac disease development.
Sample collection every six months until age 5
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Study to Identify Targets of Disease-Related T Cells in Adults with Autoimmune Diseases
Phase 1 Study to Assess Safety and Tolerability of a Single Oral Dose of HB-2121 for Diagnosing Celiac Disease in Adults
Multicenter Study to Develop and Validate an AI System for Detecting Small Bowel Damage in Celiac Disease and Other Enteropathies
Armenian Nationwide Registry for Patients with Systemic Autoimmune and Autoinflammatory Diseases
Tracking Disease Progress and Treatment Effects
Studying Genetic and Biological Differences in Coeliac Disease and Dermatitis Herpetiformis to Improve Personalized Care
Study of Genomic, Environmental, Microbiome, and Metabolomic Factors in Infants at Risk for Celiac Disease
Improving Capsule Endoscopy Diagnosis Using Artificial Intelligence to Reduce Reading Time and Enhance Accuracy
Study of Omega-3 Supplements with Gluten-Free Diet for Adults Newly Diagnosed with Celiac Disease to Reduce Inflammation and Improve Gut Health
Phase II Study of ZED1227 to Treat Symptoms in Adults With Celiac Disease Not Improved by a Gluten-Free Diet
Study of the SIMBA Capsule to Collect Samples from the Small Intestine
to Understand Gut Microbiome in Various Diseases
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Multi-omics analysis reveals the influence of genetic and environmental risk factors on developing gut microbiota in infants at risk of celiac disease.
Maureen M Leonard, Hiren Karathia, Meritxell Pujolassos...